RECRUITING

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Official Title

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Quick Facts

Study Start:2019-02-28
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03883412

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 21-60
  2. * A1C ≤ 8.5%
  3. * Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
  4. * On stable dose of oral hypoglycemic agents \>4 months
  5. * On stable dose of other medications for \>4 months
  1. * Taking Insulin
  2. * Smoking presently or in the past 6 months
  3. * BP \>160/90
  4. * BMI \>35
  5. * Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
  6. * History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
  7. * Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
  8. * Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
  9. * Pregnant or breastfeeding.
  10. * Known hypersensitivity to perflutren (contained in Definity)

Contacts and Locations

Study Contact

Lee Hartline, MEd
CONTACT
434-924-5247
lmh9d@virginia.eud
Linda Jahn, RN, MEd
CONTACT
434-924-1134
las6e@virginia.edu

Principal Investigator

Zhenqi Liu, MD
PRINCIPAL_INVESTIGATOR
University of Virginia, Department of Endocrinoolgy

Study Locations (Sites)

University of Virginia
Charlottesville, Virginia, 22906
United States

Collaborators and Investigators

Sponsor: University of Virginia

  • Zhenqi Liu, MD, PRINCIPAL_INVESTIGATOR, University of Virginia, Department of Endocrinoolgy

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-02-28
Study Completion Date2025-12

Study Record Updates

Study Start Date2019-02-28
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Type2 Diabetes